Kala Bio (KALA) Capital Expenditures (2016 - 2025)
Kala Bio (KALA) posted Capital Expenditures of -$159000.0 for Q4 2025, down 15800.0% sequentially from -$1000.0 in Q3 2025, and down 330.43% YoY from $69000.0 in Q4 2024.
Kala Bio (KALA) Capital Expenditures (2016 - 2025) Analysis & Trends
Kala Bio has reported Capital Expenditures for 10 years, with the latest figure at -$159000.0 in Q4 2025.
- Quarterly Capital Expenditures fell 330.43% year-over-year to -$159000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$144000.0 (down 169.23% YoY) and the FY2025 annual result came in at -$144000.0, down 169.23% from the prior year.
- Capital Expenditures retreated to -$159000.0 in Q4 2025 per KALA's latest filing, from -$1000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $329000.0 in Q3 2021 and troughed at -$459000.0 in Q4 2023.
- A 5-year average of $70350.0 and a median of $53500.0 in 2022 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 639.47% in 2023, down 2186.36% in 2023.
- Over 5 years, Capital Expenditures stood at $12000.0 in 2021, then surged by 83.33% to $22000.0 in 2022, then sank by 2186.36% to -$459000.0 in 2023, then jumped by 115.03% to $69000.0 in 2024, then sank by 330.43% to -$159000.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$159000.0, -$1000.0, and $9000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 251.02 Mn |
| 10 | Kala Bio | 9.87 Mn | 9.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -159,000.00 |
| Dec 31, 2025 | -159,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Jun 30, 2025 | 9,000.00 |
| Jun 30, 2025 | 9,000.00 |
| Mar 31, 2025 | 7,000.00 |
| Mar 31, 2025 | 7,000.00 |
| Dec 31, 2024 | 69,000.00 |
| Dec 31, 2024 | 69,000.00 |
| Sep 30, 2024 | 90,000.00 |
| Sep 30, 2024 | 90,000.00 |
| Jun 30, 2024 | 36,000.00 |
| Jun 30, 2024 | 36,000.00 |
| Mar 31, 2024 | 13,000.00 |
| Mar 31, 2024 | 13,000.00 |
| Dec 31, 2023 | -459,000.00 |
| Dec 31, 2023 | -459,000.00 |
| Sep 30, 2023 | 281,000.00 |
| Sep 30, 2023 | 281,000.00 |